Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Arnie Levine and the MDM2-p53 Discovery: A postdoctoral fellow's perspective.

Zambetti GP.

J Mol Cell Biol. 2019 Jul 16. pii: mjz073. doi: 10.1093/jmcb/mjz073. [Epub ahead of print] No abstract available.

PMID:
31310653
2.

From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion.

Quinn EA, Maciaszek JL, Pinto EM, Phillips AH, Berdy D, Khandwala M, Upadhyaya SA, Zambetti GP, Kriwacki RW, Ellison DW, Nichols KE, Kesserwan C.

Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4). pii: a003921. doi: 10.1101/mcs.a003921. Print 2019 Aug.

3.

KDM5A Regulates a Translational Program that Controls p53 Protein Expression.

Hu D, Jablonowski C, Cheng PH, AlTahan A, Li C, Wang Y, Palmer L, Lan C, Sun B, Abu-Zaid A, Fan Y, Brimble M, Gamboa NT, Kumbhar RC, Yanishevski D, Miller KM, Kang G, Zambetti GP, Chen T, Yan Q, Davidoff AM, Yang J.

iScience. 2018 Nov 30;9:84-100. doi: 10.1016/j.isci.2018.10.012. Epub 2018 Oct 17.

4.

Spatial trends in congenital malformations and stream water chemistry in Southern Brazil.

Ibañez HC, Melanda VS, Gerber VKQ, Licht OAB, Ibañez MVC, Aguiar Júnior TR, Mello RG, Komechen H, Andrade DP, Picharski GL, Figueiredo DPG, Pianovski MAD, Figueiredo MMO, Custódio G, Parise IZS, Castilho LM, Paraizo MM, Edinger C, Fiori CMCM, Pedrini H, Kiesel Filho N, Fabro ALMR, Fachin RD, Ogradowski KRP, Parise GA, Saldiva PHN, Legal EF, Rosati R, Rodriguez-Galindo C, Ribeiro RC, Zambetti GP, Lalli E, Figueiredo BC.

Sci Total Environ. 2019 Feb 10;650(Pt 1):1278-1291. doi: 10.1016/j.scitotenv.2018.09.061. Epub 2018 Sep 5.

PMID:
30308815
5.

Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.

Pinto EM, Hamideh D, Bahrami A, Orr BA, Lin T, Pounds S, Zambetti GP, Pappo AS, Gajjar A, Agnihotri S, Broniscer A.

Acta Neuropathol. 2018 Aug;136(2):315-326. doi: 10.1007/s00401-018-1814-2. Epub 2018 Feb 10.

6.

Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.

Pinto EM, Rodriguez-Galindo C, Pounds SB, Wang L, Clay MR, Neale G, Garfinkle EAR, Lam CG, Levy CF, Pappo AS, Zambetti GP, Ribeiro RC.

J Clin Oncol. 2017 Dec 10;35(35):3956-3963. doi: 10.1200/JCO.2017.74.2460. Epub 2017 Oct 23.

7.

The Inherited p53 Mutation in the Brazilian Population.

Achatz MI, Zambetti GP.

Cold Spring Harb Perspect Med. 2016 Dec 1;6(12). pii: a026195. doi: 10.1101/cshperspect.a026195. Review.

8.

Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study.

Pinto EM, Rodriguez-Galindo C, Choi JK, Pounds S, Liu Z, Neale G, Finkelstein D, Hicks JM, Pappo AS, Figueiredo BC, Ribeiro RC, Zambetti GP.

Clin Cancer Res. 2016 Dec 15;22(24):6247-6255. Epub 2016 Jun 15.

9.

Genomic landscape of paediatric adrenocortical tumours.

Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, Rodriguez-Galindo C, Lund TC, Mardis ER, Wilson RK, Boggs K, Yergeau D, Cheng J, Mulder HL, Manne J, Jenkins J, Mastellaro MJ, Figueiredo BC, Dyer MA, Pappo A, Zhang J, Downing JR, Ribeiro RC, Zambetti GP.

Nat Commun. 2015 Mar 6;6:6302. doi: 10.1038/ncomms7302.

10.

Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.

Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, Malkin D.

J Clin Oncol. 2015 Feb 20;33(6):602-9. doi: 10.1200/JCO.2013.52.6863. Epub 2015 Jan 12.

11.

The p53-induced factor Ei24 inhibits nuclear import through an importin β-binding-like domain.

Lieu KG, Shim EH, Wang J, Lokareddy RK, Tao T, Cingolani G, Zambetti GP, Jans DA.

J Cell Biol. 2014 May 12;205(3):301-12. doi: 10.1083/jcb.201304055.

12.

Expanding the reach of the p53 tumor suppressor network.

Zambetti GP.

Cell Death Differ. 2014 Apr;21(4):505-6. doi: 10.1038/cdd.2014.13. No abstract available.

13.

Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4.

Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM.

Cell Rep. 2014 Jan 30;6(2):271-7. doi: 10.1016/j.celrep.2013.12.020. Epub 2014 Jan 9.

14.

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.

Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H.

J Biol Chem. 2014 Feb 14;289(7):4083-94. doi: 10.1074/jbc.M113.530303. Epub 2013 Dec 23.

15.

Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.

Custódio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC.

J Clin Oncol. 2013 Jul 10;31(20):2619-26. doi: 10.1200/JCO.2012.46.3711. Epub 2013 Jun 3.

16.

MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma.

van der Deen M, Taipaleenmäki H, Zhang Y, Teplyuk NM, Gupta A, Cinghu S, Shogren K, Maran A, Yaszemski MJ, Ling L, Cool SM, Leong DT, Dierkes C, Zustin J, Salto-Tellez M, Ito Y, Bae SC, Zielenska M, Squire JA, Lian JB, Stein JL, Zambetti GP, Jones SN, Galindo M, Hesse E, Stein GS, van Wijnen AJ.

J Biol Chem. 2013 Jul 19;288(29):21307-19. doi: 10.1074/jbc.M112.445890. Epub 2013 May 29.

17.

PUMA and BIM are required for oncogene inactivation-induced apoptosis.

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH.

Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.

18.

Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.

Pinto EM, Morton C, Rodriguez-Galindo C, McGregor L, Davidoff AM, Mercer K, Debelenko LV, Billups C, Ribeiro RC, Zambetti GP.

Clin Cancer Res. 2013 Apr 1;19(7):1740-7. doi: 10.1158/1078-0432.CCR-12-3354. Epub 2013 Feb 13.

19.

Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.

Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, Jeffers JR, Rhodes M, Anderson S, Oravecz T, Hunger SP, Timakhov RA, Zhang R, Balachandran S, Zambetti GP, Testa JR, Look AT, Wiest DL.

Blood. 2012 Nov 1;120(18):3764-73. doi: 10.1182/blood-2012-03-415349. Epub 2012 Sep 13.

20.

SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes.

Letouzé E, Rosati R, Komechen H, Doghman M, Marisa L, Flück C, de Krijger RR, van Noesel MM, Mas JC, Pianovski MA, Zambetti GP, Figueiredo BC, Lalli E.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1284-93. doi: 10.1210/jc.2012-1184. Epub 2012 Apr 26.

PMID:
22539591
21.

Context-dependent enhancement of induced pluripotent stem cell reprogramming by silencing Puma.

Lake BB, Fink J, Klemetsaune L, Fu X, Jeffers JR, Zambetti GP, Xu Y.

Stem Cells. 2012 May;30(5):888-97. doi: 10.1002/stem.1054.

22.

An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers.

Pinto EM, Ribeiro RC, Li J, Taja-Chayeb L, Carrasco LF, de Lourdes Peña-Torres M, Vidal-Millán S, Maldonado-Mtz H, Dueñas-González A, McGregor L, Zambetti GP.

Oncogenesis. 2012 Feb 20;1:e1. doi: 10.1038/oncsis.2012.1.

23.

The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors.

Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C.

Mol Cell Endocrinol. 2012 Mar 31;351(1):37-43. doi: 10.1016/j.mce.2011.10.015. Epub 2011 Oct 23. Review.

PMID:
22040600
24.

Genetically defining the mechanism of Puma- and Bim-induced apoptosis.

Garrison SP, Phillips DC, Jeffers JR, Chipuk JE, Parsons MJ, Rehg JE, Opferman JT, Green DR, Zambetti GP.

Cell Death Differ. 2012 Apr;19(4):642-9. doi: 10.1038/cdd.2011.136. Epub 2011 Oct 21.

25.

Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Wasserman JD, Zambetti GP, Malkin D.

Mol Cell Endocrinol. 2012 Mar 31;351(1):101-10. doi: 10.1016/j.mce.2011.09.010. Epub 2011 Sep 10. Review.

26.

Diving into in vivo p53 tumor suppressor studies using a new platform mouse model.

Zambetti GP.

Cell Cycle. 2011 Aug 15;10(16):2619. Epub 2011 Aug 15. No abstract available.

PMID:
21841367
27.

TP53-Associated Pediatric Malignancies.

Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP.

Genes Cancer. 2011 Apr;2(4):485-90. doi: 10.1177/1947601911409745.

28.

The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo.

Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS.

Cell Cycle. 2011 Jul 15;10(14):2380-9. Epub 2011 Jul 15.

29.

Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors.

Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL.

J Immunol. 2011 Jul 15;187(2):664-75. doi: 10.4049/jimmunol.1100029. Epub 2011 Jun 20.

30.

Placental alkaline phosphatase in pediatric adrenocortical cancer.

Boechat GA, Stinghen ST, Custódio G, Pianovski MA, Figueiredo FR, Jenkins J, Zambetti GP, Ribeiro RC, Figueiredo BC.

J Pediatr Hematol Oncol. 2011 May;33(4):e149-53. doi: 10.1097/MPH.0b013e3182099a80.

PMID:
21516013
31.

Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O'Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER.

JAMA. 2011 Apr 20;305(15):1568-76. doi: 10.1001/jama.2011.473.

32.
33.

6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death.

Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL.

Mol Neurodegener. 2011 Jan 6;6(1):2. doi: 10.1186/1750-1326-6-2.

34.

The p53-target gene puma drives neutrophil-mediated protection against lethal bacterial sepsis.

Garrison SP, Thornton JA, Häcker H, Webby R, Rehg JE, Parganas E, Zambetti GP, Tuomanen EI.

PLoS Pathog. 2010 Dec 23;6(12):e1001240. doi: 10.1371/journal.ppat.1001240.

35.

Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells.

Coloff JL, Mason EF, Altman BJ, Gerriets VA, Liu T, Nichols AN, Zhao Y, Wofford JA, Jacobs SR, Ilkayeva O, Garrison SP, Zambetti GP, Rathmell JC.

J Biol Chem. 2011 Feb 18;286(7):5921-33. doi: 10.1074/jbc.M110.179101. Epub 2010 Dec 15.

36.

BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.

Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH.

Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.

37.

Genetics and genomics of childhood adrenocortical tumors.

El Wakil A, Doghman M, Latre De Late P, Zambetti GP, Figueiredo BC, Lalli E.

Mol Cell Endocrinol. 2011 Apr 10;336(1-2):169-73. doi: 10.1016/j.mce.2010.11.008. Epub 2010 Nov 19.

PMID:
21094206
38.

Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor.

Pinto EM, Ribeiro RC, Kletter GB, Lawrence JP, Jenkins JJ, Wang J, Shurtleff S, McGregor L, Kriwacki RW, Zambetti GP.

Fam Cancer. 2011 Mar;10(1):141-6. doi: 10.1007/s10689-010-9392-z.

39.

Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies.

Ribeiro RC, Pinto EM, Zambetti GP.

Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):477-90. doi: 10.1016/j.beem.2010.03.002. Review.

PMID:
20833338
40.

Puma is required for p53-induced depletion of adult stem cells.

Liu D, Ou L, Clemenson GD Jr, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y.

Nat Cell Biol. 2010 Oct;12(10):993-8. doi: 10.1038/ncb2100. Epub 2010 Sep 5.

41.

Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E.

Cancer Res. 2010 Jun 1;70(11):4666-75. doi: 10.1158/0008-5472.CAN-09-3970. Epub 2010 May 18.

42.

Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation.

Yu H, Shen H, Yuan Y, XuFeng R, Hu X, Garrison SP, Zhang L, Yu J, Zambetti GP, Cheng T.

Blood. 2010 Apr 29;115(17):3472-80. doi: 10.1182/blood-2009-10-248278. Epub 2010 Feb 22.

43.

Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis.

Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH.

Mol Cell. 2009 Nov 13;36(3):487-99. doi: 10.1016/j.molcel.2009.09.030.

44.

JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis.

Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ.

J Biol Chem. 2009 Sep 25;284(39):26591-602. doi: 10.1074/jbc.M109.022491. Epub 2009 Jul 28.

45.

Assays to measure p53-dependent and -independent apoptosis.

Phillips DC, Garrison SP, Jeffers JR, Zambetti GP.

Methods Mol Biol. 2009;559:143-59. doi: 10.1007/978-1-60327-017-5_11.

PMID:
19609755
46.

PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis.

Wang P, Qiu W, Dudgeon C, Liu H, Huang C, Zambetti GP, Yu J, Zhang L.

Cell Death Differ. 2009 Sep;16(9):1192-202. doi: 10.1038/cdd.2009.51. Epub 2009 May 15.

47.

Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

Rossi M, Bang JK, Mazur S, Iera JA, Phillips DC, Zambetti GP, Appella DH.

Bioorg Med Chem Lett. 2009 May 1;19(9):2429-34. doi: 10.1016/j.bmcl.2009.03.067. Epub 2009 Mar 21.

48.

Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function.

Steimer DA, Boyd K, Takeuchi O, Fisher JK, Zambetti GP, Opferman JT.

Blood. 2009 Mar 19;113(12):2805-15. doi: 10.1182/blood-2008-05-159145. Epub 2008 Dec 8.

49.

Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.

Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA.

BMC Cancer. 2008 Dec 1;8:357. doi: 10.1186/1471-2407-8-357. Erratum in: BMC Cancer. 2011;11:152.

50.

High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation.

Rosati R, Cerrato F, Doghman M, Pianovski MA, Parise GA, Custódio G, Zambetti GP, Ribeiro RC, Riccio A, Figueiredo BC, Lalli E.

Cancer Genet Cytogenet. 2008 Oct;186(1):19-24. doi: 10.1016/j.cancergencyto.2008.05.010.

Supplemental Content

Loading ...
Support Center